MoleculeX Co., Ltd.

MoleculeX Co., Ltd. is a Taiwanese startup focused on developing mucosal adhesives for trans-mucosal drug delivery and wet tissue care products. The company has introduced the world's first "intraoral" wound dressing designed to treat severe oral ulcers resulting from cancer treatment. Additionally, they have created a large-area intraoral wound dressing utilizing their MuCover® mucoadhesive film technology, which has been approved by the Taiwan FDA in 2023. The application of MuCover® enables simple, precise, and sustained drug delivery in challenging locations, positioning it as a transmucosal delivery system for the development of 505(b)(2) new drugs. The degradable design of MuCover® reduces the risk of adhesive-related injury to the mucosal tissue, making it an ideal solution for oral mucosal wounds.

MoleculeX, founded in 2021, has the potential to address the major side effects of cancer therapy, such as oral mucositis, which can cause extreme pain and lead to treatment discontinuation. With their innovative technology and FDA approval, MoleculeX is well-positioned to become a standard of care for oral mucosal wounds. As the company continues to progress, it presents an interesting investment opportunity for venture capital firms looking to support groundbreaking solutions in the healthcare industry.